Is CBD a dietary ingredient or a drug? US FDA ‘appears to have changed its mind’

Frustration with the lack of a clear regulatory pathway to market for CBD products in the US is demonstrated by recent industry responses to the denial of a new dietary ingredient (NDI) approval by the US Food and Drug Administration (FDA) for full spectrum hemp extracts.

The nub of the problem appears to be disagreement between the FDA and the industry over whether CBD should be classed as a drug or a dietary supplement.


Restricted content. Do you want to read more?